Tissue factor–Factor VIIa complex (TF-FVIIa)

The Tissue factor–Factor VIIa (TF-FVIIa) complex, also known as the extrinsic tenase complex, is the primary physiological initiator of the blood coagulation cascade (StatPearls, 2023). It forms when the transmembrane protein Tissue Factor (TF/CD142) is exposed to the blood following vascular injury and binds to circulating Factor VII or its activated form, Factor VIIa (UniProt P13726). This complex functions as a serine protease that catalyzes the activation of Factor X and Factor IX, leading to a burst of thrombin generation and subsequent fibrin clot formation (PubMed, PMID: 15141316). Beyond hemostasis, the TF-FVIIa complex triggers intracellular signaling via protease-activated receptors (PARs), influencing inflammation, angiogenesis, and tumor progression (PubMed, PMID: 22451470). In pathological states, overexpression of TF and the resulting activity of the TF-FVIIa complex are linked to thrombosis, cardiovascular disease, and the growth of various solid tumors. Therapeutic strategies targeting this complex include direct inhibitors of FVIIa, inhibitors of the TF-FVIIa interaction, and antibody-drug conjugates that utilize TF as a cell-surface marker for cytotoxic delivery. For example, Tisotumab vedotin is an FDA-approved antibody-drug conjugate that targets TF-expressing cells in cervical cancer (FDA, 2021). Safety concerns for drugs targeting this complex primarily revolve around the risk of significant bleeding due to the impairment of the body's primary clotting mechanism.

Other names

Extrinsic tenase complexTF-FVIIa complexThromboplastin-Factor VIIa complexCD142-Factor VIIa complexCoagulation factor III-VIIa complex

Inhibition of the extrinsic tenase complex to prevent the proteolytic activation of Factor X and Factor IX, or targeted delivery of cytotoxic agents to TF-expressing cells.